Methods for Diagnosing, Staging, Predicting Risk for Developing and Identifying Treatment Responders for Rheumatoid Arthritis

ABSTRACT

Disclosed are methods for diagnosing, staging, and predicting risk for developing rheumatoid arthritis and other inflammatory diseases, and methods for identifying treatment responders and non-responders.

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/332,081, filed May 6, 2010; U.S. Provisional Patent Application Ser. No. 61/428,500, filed Dec. 30, 2010; and U.S. Provisional Patent Application Ser. No. 61/444,702, filed Feb. 19, 2011. Each of the above-referenced applications are incorporated by reference herein in their entirety.

BACKGROUND

Rheumatoid Arthritis (RA) is characterized by synovial inflammation and destruction of joint cartilage and bone. Such destruction is caused in part by the ongoing synthesis of proinflammatory cytokines and matrix metalloproteinases. Autoimmune diseases, such as RA have been classically viewed as Th1 (CD4+ T helper cell-induced; interferon-gamma, for example, is produced, which activates the bactericidal activities of macrophages and induces B-cells to make opsonizing (coating) antibodies, leading to cellular immunity) and not Th2 (CD4+ T helper cell-induced; interleukin 4, for example, is released, which results in the activation of B-cells to make neutralizing antibodies, leading to humoral immunity) disorders. However, recent studies have brought this thought into questions (Lubberts; Seminars in Immunopathology 32(1), 43-53 (2010)). For example, IL-17a (a proinflammatory cytokine) is present at sufficient concentrations in the synovial fluid of RA patient joints that it can be detected. However, this and other cytokines cannot be detected in serum or plasma obtained from the same patients. There is a need to detect biomarkers in serum or plasma that are related to RA and other inflammatory disorders (e.g., Crohn's Disease, Inflammatory Bowel Disease (IBD), ulcerative colitis, psoriasis, Chronic Obstructive Pulmonary Disease (COPD)) so that RA can be more readily or effectively diagnosed and staged, risk for developing RA or other inflammatory disorder can be more readily or effectively assessed, and patients who are responders and non-responders to RA therapy can be more readily or effectively identified.

SUMMARY OF THE INVENTION

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorders (e.g., Crohn's Disease, Inflammatory Bowel Disease (IBD), ulcerative colitis, psoriasis, Chronic Obstructive Pulmonary Disease (COPD)) in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A (Interleukin 17A), IL-17A/F (Interleukin 17A/17F heterodimer), and IL-17F (Interleukin 17F), and optionally one or more of IL-1β (Interleukin 1-beta), IL-6 (Interleukin 6), totMMP-9 (total precursor and active matrix metallopeptidase 9 (or gelatinase B)), proMMP-9 (precursor protein of matrix metallopeptidase 9), cTnI (cardiac troponin I), and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and/or IL-17F greater than about 0.18 pg/ml, 1.35 pg/ml and 116 pg/ml, respectively, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorders. In certain aspects, subject IL-17A, IL-17A/F and/or IL-17F biomarker concentrations are compared to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched healthy volunteers, to predict whether they have a greater than normal risk of developing RA or other inflammatory disorders. In other aspects, additional biomarker (e.g., IL-1β, IL-6, totMMP-9, proMMP-9, cTnI) concentrations are determined and utilized to predict whether a subject has a greater than normal risk of developing RA or other inflammatory disorders. In some aspects values are used, and in others comparisons to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched volunteers are utilized.

In another aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorders in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and/or IL-17F greater than about 0.18 pg/ml, 1.35 pg/ml and 116 pg/ml, respectively, the subject has an increased likelihood of developing RA or other inflammatory disorders. In certain aspects, subject IL-17A, IL-17A/F and/or IL-17F biomarker concentrations are compared to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched healthy volunteers, to determine the likelihood of the subject developing RA. In other aspects, additional biomarker (e.g., IL-1β, IL-6, totMMP-9, proMMP-9, cTnI) concentrations are determined and utilized to determine the likelihood of the subject developing RA or other inflammatory disorders. In some aspects values are used, and in others comparisons to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched volunteers are utilized.

In another aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the RA patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the RA or other inflammatory disorder patient, obtaining a second sample from the RA patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the RA patient has a first concentration of IL-17A, IL-17A/F and/or IL-17F greater than about 0.18 pg/ml, 1.35 pg/ml and 116 pg/ml, respectively, and a second concentration of IL-17A, IL-17A/F and/or IL-17F less than about 0.18 pg/ml, 1.35 pg/ml and 116 pg/ml, respectively, the RA or other inflammatory disorder patient is identified as RA or other inflammatory disorder patients who responds to therapy.

In another aspect, the disclosure provides methods for predicting the rate of inflammatory disease progression in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of none, one or more than one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one, one or more or at least two of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a slow rate, medium rate or high rate of inflammatory disease progression.

In another aspect, the disclosure provides methods for predicting the likelihood of inflammatory disease remission in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of none, one or more than one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one, one or more or at least two of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a high likelihood, medium likelihood or a low likeihood of inflammatory disease remission.

In another aspect, the disclosure provides methods for determining the severity of inflammatory disease in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of one or more of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of none, one, one or more, or two or more or one of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is determined to have mild, moderate or severe inflammatory disease.

For all of the above aspects related to predicting the rate of inflammatory disease progression, predicting the likelihood of inflammatory disease remission, or determining the severity of inflammatory disease, the inflammatory disease is selected from the group consisting of RA, Crohn's Disease, IBD, ulcerative colitis, psoriasis, and COPD.

In certain aspects, subject IL-17A, IL-17A/F and/or IL-17F biomarker concentrations are compared to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched healthy volunteers, to identify RA or other inflammatory disorder patients who respond to therapy. In other aspects, additional biomarker (e.g., IL-1β, IL-6, totMMP-9, proMMP-9, cTnI) concentrations are determined and utilized to identify RA or other inflammatory disorder patients who respond to therapy. In some aspects values are used, and in others comparisons to average biomarker concentrations for healthy volunteers, and in aspects age- and/or gender-matched volunteers are utilized.

In another aspect, the disclosure provide method for determining inflammatory disease in a patient. The method includes detecting the concentration of more or more the following markers in a patient sample: IL-17A, IL-17F, IL-17A/F, IL-1β, IL-6, totMMP-9, proMMP-9, and cTnI, comparing the level of the one or more markers to the level in a normal population of healthy volunteers; and determining that the patient has inflammatory disease when the concentration of IL-17A, IL-17F, IL-17A/F, IL-6, or cTnI are elevated relative to the normal population, or totMMP-9, proMMP-9, or IL-1β are decreased relative to the normal population. In certain aspects, the disease is RA and the one or more markers include the combination of IL-17F & IL-17A, the combination of IL-17A and IL-17 A/F, or the combination of IL-17F and IL-17 A/F.

Other aspects and embodiments of the invention will become apparent to those of skill in the art in view of the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates various biomarker levels in RA patients versus healthy volunteers. The three hash marks through each data set represent mean and one standard deviation above and below the mean. Concentrations of several markers are significantly elevated or attenuated in RA patients (P-values are indicated).

FIG. 2 provides a larger-scale view of select results illustrated in FIG. 1. The three hash marks through each data set represent mean and upper and lower quartile divisions (rather than mean and one standard deviation above and below the mean).

FIG. 3 illustrates the heretofore unknown importance of the IL-17A, IL-17F, IL-17A/F heterodimer in RA biology. Only 6% of RA patients in the sample had neither IL-17A nor IL-17F present at elevated concentrations over HV. All RA patients had at least one of IL-17A, IL-17F, and IL-17A/F heterodimer present at elevated concentrations over HV.

FIG. 4 shows box plots of the markers that best classify RA along with a box plot for TNFα.

FIG. 5 shows that the combination of IL-17F & IL-17A as biomarkers for RA were 100% predictive of disease.

FIG. 6 shows that the combination of IL-17A and IL-17 A/F as biomarkers for RA perform very well in predicting disease.

FIG. 7 shows that the combination of IL-17F and IL-17 A/F as biomarkers for RA perform very well in predicting disease.

DETAILED DESCRIPTION OF THE INVENTION

All publications, patent applications, patents and other references mentioned herein, if not otherwise indicated, are explicitly incorporated by reference.

Unless otherwise defined, the technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Expansion and clarification of some terms are provided herein.

As used herein, the term “subject” refers to a mammal that can be afflicted by a rheumatoid arthritis, but may or may not have such a disease. Typically, the terms “subject” and “patient” are used herein interchangeably in reference. In various embodiments, the subject is a human.

As used herein, the term “sample” is taken broadly to include any sample suitable for the methods described herein. Typically, the sample is a biological sample such as, for example, a biological fluid. Such fluids can include, without limitation, bronchoalveolar lavage fluid (BAL), blood, serum, plasma, urine, nasal swab, cerebrospinal fluid, pleural fluid, synovial fluid, peritoneal fluid, amniotic fluid, gastric fluid, lymph fluid, interstitial fluid, tissue homogenate, cell extracts, saliva, sputum, stool, physiological secretions, tears, mucus, sweat, milk, semen, seminal fluid, vaginal secretions, fluid from ulcers and other surface eruptions, blisters, and abscesses, and extracts of tissues including biopsies of normal, malignant, and suspect tissues or any other constituents of the body which may contain the target particle of interest. Other similar specimens such as cell or tissue culture or culture broth are also of interest. In some embodiments, the sample is a blood sample. In some embodiments the sample is a plasma sample. In some embodiments the sample is a serum sample.

As used herein, the term “healthy volunteer average concentrations” refers to the average concentration of the various biomarkers described herein for at least two subjects who do not have RA (e.g., HV). Preferably, average concentration values are calculated from biomarker concentrations measured in larger groups of HVs. Healthy volunteer average concentrations are provided herein, but one of skill in the art may also measure biomarker concentrations in one or more populations of subjects lacking RA utilizing an apparatus capable of sensitively measuring the concentrations of biomarkers described herein and calculating the average values for each biomarker in such HV populations.

As used herein, the term “therapy” refers to the administration of any medical treatment (e.g., pharmaceuticals) or interventional treatment (e.g., surgery) to affect RA or the biomarkers relevant to RA described herein.

As used herein, the term “substantially the same as” refers to ± about 25%, ± about 20%, ± about 15%, ± about 10%, ± about 5%, ± about 3%, ± about 2%, or ± about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ± about 20%, ± about 15%, ± about 10%, or ± about 5%, ± about 3%, ± about 2%, or ± about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ± about 15%, ± about 10%, ± about 5%, ± about 3%, ± about 2%, or ± about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ± about 10%, ± about 5%, ± about 3%, ± about 2%, or ± about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ± about 5%, ± about 3%, ± about 2%, or ± about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ± about 3%, ± about 2%, or ± about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ± about 2%, or ± about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ± about 1% of the healthy volunteer average concentrations of a biomarker.

As used herein, the term “CV” refers to the coefficient of variance. In some aspects “substantially the same as” refers to ± about 10%, ± about 5%, ± about 3%, ± about 2%, or ± about 1% of the healthy volunteer average concentrations of a biomarker. In some aspects “substantially the same as” refers to ± about 5%, ± about 3%, ± about 2%, or ± about 1% of the healthy volunteer average concentrations of a biomarker.

As used herein, the term “average CV” refers to average of the coefficient of variance obtained for all samples tested in triplicate.

As used herein, the term “LoD” refers to the limit of detection, defined as 2 standard deviations above the zero calibrator.

As used herein, the term “LLoQ” refers to the lower limit of quantification, defined from data generated off of the standard curve. Specifically, the back interpolated values of standards in triplicate provide CVs<20% and a bias<20% of the expected values.

As used herein, the terms “inflammatory disorder” and “inflammatory disease” refer to any of a number of conditions in which inflammation is increased over normal subjects. Non-limiting examples of inflammatory disorders are rheumatoid arthritis, Crohn's Disease, Inflammatory Bowel Disease, ulcerative colitis, psoriasis, and Chronic Obstructive Pulmonary Disease (COPD).

The American College of Rheumatology has developed criteria to aid in determining the progression, remission, and functional status of patients with RA.

Progression of RA (clinical and radiologic staging) is classified as follows: Stage 1 (early RA) is characterized by no destructive changes observed upon roentgenographic examination; radiographic evidence of osteoporosis is possible. Stage II (moderate progression) is characterized by radiographic evidence of periarticular osteoporosis, with or without slight subchondral bone destruction; slight cartilage destruction is possible; joint mobility is possibly limited; no joint deformities are observed; adjacent muscle atrophy is observed; extra-articular soft-tissue lesions (eg, nodules, tenosynovitis) are possible. Stage III (severe progression) is characterized by radiographic evidence of cartilage and bone destruction in addition to periarticular osteoporosis; joint deformity (e.g., subluxation, ulnar deviation, hyperextension) without fibrous or bony ankylosis; extensive muscle atrophy; and extra-articular soft-tissue lesions (eg, nodules, tenosynovitis) are possible. Stage IV (terminal progression) is characterized by fibrous or bony ankylosis in addition to the criteria of Stage III.

Remission of RA is defined as ≧5 of the following conditions occurring for at least 2 consecutive months: duration of morning stiffness does not exceed 15 minutes; no fatigue; no joint pain; no joint tenderness or pain with motion; no soft-tissue swelling in joints or tendon sheaths; ESR (erythrocyte sedimentation rate) of less than 30 millimeters/hour (mm/h) in a female or less than 20 mm/h in a male.

Functional status of patients with RA is defined as follows: Class I individuals are completely able to perform usual activities of daily living. Class II individuals are able to perform usual self-care and vocational activities but limited in avocational activities. Class III individuals are able to perform usual self-care activities but limited in vocational and avocational activities. Class IV individuals are limited in ability to perform usual self-care, vocational, and avocational activities.

We hypothesized that the concentrations of many cytokines and matrix metalloproteinases in blood serum or plasma may parallel the relative abundance in inflamed joints of RA patients, and that a highly sensitive assay could be used to measure them. Further, we hypothesized that differences in cytokine concentrations could be determined between RA patients and otherwise healthy matched controls with such highly sensitive assays. Herein we describe the use of a highly sensitive immunoassay system to measure cytokines and other biomarkers in blood plasma obtained from RA patients and healthy control subjects and describe differences in biomarker concentrations that we have discovered between these two study groups. The measurement of differences in the biomarker concentrations, either up- or down-regulated, singly or in combination, in RA patients versus control subjects provides opportunities for better (e.g., simpler, earlier, faster) disease diagnosis, disease staging, risk classification, and/or identification of therapy responders/non-responders.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations or other inflammatory disorder tions for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for predicting the risk for developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing RA or other inflammatory disorder.

For any of the above aspects related to predicting the risk for developing RA or other inflammatory disorder in a subject, the methods pertain to predicting the risk for developing RA.

For any of the above aspects related to predicting the risk for developing RA or other inflammatory disorder in a subject, the methods pertain to predicting the risk for developing Crohn's Disease.

For any of the above aspects related to predicting the risk for developing RA or other inflammatory disorder in a subject, the methods pertain to predicting the risk for developing Inflammatory Bowel Disease.

For any of the above aspects related to predicting the risk for developing RA or other inflammatory disorder in a subject, the methods pertain to predicting the risk for developing ulcerative colitis.

For any of the above aspects related to predicting the risk for developing RA or other inflammatory disorder in a subject, the methods pertain to predicting the risk for developing psoriasis.

For any of the above aspects related to predicting the risk for developing RA or other inflammatory disorder in a subject, the methods pertain to predicting the risk for developing Chronic Obstructive Pulmonary Disease (COPD).

In another aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

In an aspect, the disclosure provides methods for determining the likelihood of developing RA or other inflammatory disorder in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject has an increased likelihood of developing RA or other inflammatory disorder.

For any of the above aspects related to determining the likelihood of developing RA or other inflammatory disorder in a subject, the methods pertain to determining the likelihood of developing RA.

For any of the above aspects related to determining the likelihood of developing RA or other inflammatory disorder in a subject, the methods pertain to determining the likelihood of developing Crohn's Disease.

For any of the above aspects related to determining the likelihood of developing RA or other inflammatory disorder in a subject, the methods pertain to determining the likelihood of developing Inflammatory Bowel Disease.

For any of the above aspects related to determining the likelihood of developing RA or other inflammatory disorder in a subject, the methods pertain to determining the likelihood of developing ulcerative colitis.

For any of the above aspects related to determining the likelihood of developing RA or other inflammatory disorder in a subject, the methods pertain to determining the likelihood of developing psoriasis.

For any of the above aspects related to determining the likelihood of developing RA or other inflammatory disorder in a subject, the methods pertain to determining the likelihood of developing Chronic Obstructive Pulmonary Disease (COPD).

In another aspect, the disclosure provides methods for determining inflammatory disease in a patient. For example a number of markers can be used to diagnose existing inflammatory disease such as RA. FIGS. 1, 2, and 3 show the that patients with elevated levels of IL-17A, IL-17F, and IL-17A/F, either alone or in combination, are likely to be suffering from RA. Other markers, such as IL-1β, IL-6, totMMP-9, proMMP-9, and cTnI, are also useful in determining disease. Accordingly, in on aspect the disclosure is provides a method of detecting inflammatory disease by measuring the amount of one or more of IL-17A, IL-17F, IL-17A/F, IL-1β, IL-6, totMMP-9, proMMP-9, and cTnI, in a patient sample, comparing the sample to a control population, and determining whether a patient is suffering from inflammatory disease. Statistically significant differences between the patient sample and the control population (healthy volunteers) for one or more markers can be indicative of disease. As shown in FIG. 3, only 6% of RA patients in the reference population had neither IL-17A nor IL-17F present at elevated concentrations over healthy volunteers (HV). All RA patients had at least one of IL-17A, IL-17F, and IL-17A/F heterodimer present at elevated concentrations over (HV). In particular embodiments, as shown in FIGS. 5, 6 and 7, the combination of IL-17F & IL-17A, the combination of IL-17A and IL-17 A/F, or the combination of IL-17F and IL-17 A/F can be used as biomarkers in diagnosing RA.

In another aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the patient has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml and of IL-17F of less than about 116 pg/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with one or more of a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml and of IL-17F of less than about 116 pg/ml, in combination with one or more of a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, and a second concentration of one or more of IL-17A, IL-17A/F or IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F or IL-17F, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, and a second concentration of IL-17A, IL-17A/F and IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F and IL-17F, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying RA or other an inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A, IL-17A/F or IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A, IL-17A/F or IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A, IL-17A/F and IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A, IL-17A/F and IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with one or more of a concentration of IL-1β greater than about 1.1 pg/ml, a concentration of IL-6 less than about 1.0 pg/ml, or a concentration of totMMP-9 greater than about 5.0 ng/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with one or more of a concentration of IL-1β greater than about 1.1 pg/ml, a concentration of IL-6 less than about 1.0 pg/ml, or a concentration of totMMP-9 greater than about 5.0 ng/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with a concentration of IL-1β greater than about 1.1 pg/ml, a concentration of IL-6 less than about 1.0 pg/ml, and a concentration of totMMP-9 greater than about 5.0 ng/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml and of IL-17F of less than about 116 pg/ml, in combination with a concentration of IL-1β greater than about 1.1 pg/ml, a concentration of IL-6 less than about 1.0 pg/ml, and a concentration of totMMP-9 greater than about 5.0 ng/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, and a second concentration of IL-17A, IL-17A/F or IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β greater than about 1.1 pg/ml, a concentration of IL-6 less than about 1.0 pg/ml, and a concentration of totMMP-9 greater than about 5.0 ng/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, and a second concentration of IL-17A, IL-17A/F or IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β greater than about 1.1 pg/ml, a concentration of IL-6 less than about 1.0 pg/ml, and a concentration of totMMP-9 greater than about 5.0 ng/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

In an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, and a second concentration of IL-17A, IL-17A/F and IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β greater than about 1.1 pg/ml, a concentration of IL-6 less than about 1.0 pg/ml, and a concentration of totMMP-9 greater than about 5.0 ng/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

an aspect, the disclosure provides methods for identifying an RA or other inflammatory disorder patient who responds to therapy, comprising obtaining a first sample from the patient, determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample, administering a therapy to the patient, obtaining a second sample from the patient, and determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample, wherein when the subject has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, and a second concentration of IL-17A, IL-17A/F and IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β greater than about 1.1 pg/ml, a concentration of IL-6 less than about 1.0 pg/ml, and a concentration of totMMP-9 greater than about 5.0 ng/ml, the RA or other inflammatory disorder patient is identified as a patient who responds to therapy.

For any of the above aspects related to identifying an RA or other inflammatory disorder patient who responds to therapy, the methods pertain to identifying an RA patient who responds to therapy.

For any of the above aspects related to identifying an RA or other inflammatory disorder patient who responds to therapy, the methods pertain to identifying a Crohn's Disease patient who responds to therapy.

For any of the above aspects related to identifying an RA or other inflammatory disorder patient who responds to therapy, the methods pertain to identifying a Inflammatory Bowel Disease patient who responds to therapy.

For any of the above aspects related to identifying an RA or other inflammatory disorder patient who responds to therapy, the methods pertain to identifying an ulcerative colitis patient who responds to therapy.

For any of the above aspects related to identifying an RA or other inflammatory disorder patient who responds to therapy, the methods pertain to identifying a psoriasis patient who responds to therapy.

For any of the above aspects related to identifying an RA or other inflammatory disorder patient who responds to therapy, the methods pertain to identifying a COPD patient who responds to therapy.

In another aspect, the disclosure provides methods for predicting the rate of inflammatory disease progression in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of none or one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a slow rate of inflammatory disease progression.

In an aspect, the disclosure provides methods for predicting the rate of inflammatory disease progression, wherein when the concentrations of one of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one or more of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a medium rate of inflammatory disease progression.

In an aspect, the disclosure provides methods for predicting the rate of inflammatory disease progression, wherein when the concentrations of one or more of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of at least two of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a high rate of inflammatory disease progression.

In another aspect, the disclosure provides methods for predicting the likelihood of inflammatory disease remission in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of none or one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a high likelihood of inflammatory disease remission.

In an aspect, the disclosure provides methods for predicting the likelihood of inflammatory disease remission in a subject, wherein when the concentrations of one of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one or more of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a medium likelihood of inflammatory disease remission.

In an aspect, the disclosure provides methods for predicting the likelihood of inflammatory disease remission in a subject, wherein when the concentrations of one or more of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of at least two of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is predicted to have a low likelihood of inflammatory disease remission.

In another aspect, the disclosure provides methods for determining the severity of inflammatory disease in a subject, comprising obtaining a sample from the subject, determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample, wherein when the concentration of one of IL-17A is greater than 0.18 pg/ml, IL-17-F is greater than 116 pg/ml, or IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of none or one of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, or IL-6 is greater than 1.0 pg/ml, the subject is determined to have mild inflammatory disease.

In an aspect, the disclosure provides methods for determining the severity of inflammatory disease in a subject, wherein when the concentrations of at least one of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, or the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of one or more of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is determined to have moderate inflammatory disease.

In another aspect, the disclosure provides methods for determining the severity of inflammatory disease in a subject, wherein when the concentrations of at least one of IL-17A is greater than 0.18 pg/ml, the concentration of IL-17-F is greater than 116 pg/ml, and the concentration of IL-17A/F is greater than 1.35 pg/ml, and wherein when the concentration of two or more of IL-1β is less than 1.1. pg/ml, totMMP-9 is less than 5.0 ng/ml, and IL-6 is greater than 1.0 pg/ml, the subject is determined to have severe inflammatory disease.

For any of the above aspects related to predicting the rate of inflammatory disease progression, predicting the likelihood of inflammatory disease remission, or determining the severity of inflammatory disease, the inflammatory disease is RA, Crohn's Disease, IBD, ulcerative colitis, psoriasis, or COPD.

For any of the above aspects related to predicting the rate of inflammatory disease progression, predicting the likelihood of inflammatory disease remission, or determining the severity of inflammatory disease, the inflammatory disease is RA.

For any of the above aspects related to predicting the rate of inflammatory disease progression, predicting the likelihood of inflammatory disease remission, or determining the severity of inflammatory disease, the inflammatory disease is Crohn's Disease.

For any of the above aspects related to predicting the rate of inflammatory disease progression, predicting the likelihood of inflammatory disease remission, or determining the severity of inflammatory disease, the inflammatory disease is IBD.

For any of the above aspects related to predicting the rate of inflammatory disease progression, predicting the likelihood of inflammatory disease remission, or determining the severity of inflammatory disease, the inflammatory disease is ulcerative colitis.

For any of the above aspects related to predicting the rate of inflammatory disease progression, predicting the likelihood of inflammatory disease remission, or determining the severity of inflammatory disease, the inflammatory disease is psoriasis.

For any of the above aspects related to predicting the rate of inflammatory disease progression, predicting the likelihood of inflammatory disease remission, or determining the severity of inflammatory disease, the inflammatory disease is COPD.

In various embodiments of the methods disclosed herein, concentrations of biomarkers related to RA or other inflammatory disorder comprise values that are elevated or reduced relative to the concentrations of those same biomarkers in a normal population of subjects (e.g., the HV group as provided herein). One of skill in the art may also measure biomarker concentrations in one or more HV populations utilizing an apparatus capable of sensitively measuring the concentrations of biomarkers described herein and calculate the average values for each biomarker in such HV populations.

In embodiments of the methods, the sample can be a single sample from the subject. In some embodiments, the sample can be a series of samples taken at various points in time so that changes in concentration over time of biomarker related to RA or other inflammatory disorder can be identified and interpreted. In embodiments, the samples can be taken in over the course of hours, days, weeks, months, and years. The samples can be taken at any regular or irregular interval based on the detected concentration(s) of biomarker related to RA or other inflammatory disorder and/or the change in the concentration(s) of biomarker related to RA or other inflammatory disorder in the one or more samples over time.

In embodiments that track patient data and samples over time, such information can be taken from any known clinical study or database that maintains such patient samples and/or patient history.

Systems for Detection

As noted above, the diagnostic/prognostic methods described herein generally involve the determination of the amount of biomarker related to RA or other inflammatory disorder from one or a set of samples from a subject. Determination of concentrations of biomarker related to RA or other inflammatory disorder in the practice of the methods can be performed using any suitable apparatus or system that allow for the detection levels described herein. Such suitable apparatus, includes, but is not limited to, the systems described in Published U.S. Patent Application Nos: 2009/0159812 (Livingston); 2008/0003685 (Goix, et al.); and U.S. Pat. No. 7,572,640, all incorporated herein by reference. U.S. Pat. No. 7,572,640 describes instruments, reagents and methods for measuring analytes at levels to carry out this invention and thus identify those patients with of biomarker related to RA levels above or below the normal HV range.

EXAMPLES Example 1

The Erenna System, based upon Singulex Single Molecule Counting technology, was used for immunoassay analysis. This system has been described previously (Todd et al., Clin Chem. 53(11): 1990-1995 (2007); Todd et al., Clin Chem. 55(1):196-8 (2009); incorporated by reference). Immunoassays for the analytes described in the table below were constructed from commercially available antibodies and analytes. The immunoassay procedure used in the analyses of these analytes has been described previously as well (Todd et al., supra). All antibodies and analytes were obtained from R&D Systems (Minneapolis, Minn.) except for cTnI analyte, which was obtained from HyTest (Turku, Finland), and antibodies to cTnI, which were obtained from BiosPacific (Emeryville, Calif.). The volume of sample stated in Table 6 was added to a well in a 96 well plate, along with sufficient volume of calibrator diluent (3% BSA, Tris pH 8.0, 150 mM NaCl) to create a final volume of 100 ul for all test but for cTnI, which had a final volume of 50 ul. 100 ul of paramagnetic microparticles, and 150 ul for cTnI assays (MPs, MyOne, Invitrogen Dynal AS; approximately 5-10 ug MPs/well), coated with the capture antibody and diluted in assay buffer (1% BSA, Tris-buffered saline, pH 7.4, with 0.5 mL Triton X-100/L, and heterophile/human antimouse antibody-blocking reagents (from Scantibodies Laboratories, used per the manufacturer's recommendations)), were added to each well and incubated for about 2 hours (about 1 hour for cTnI and IL-1β). MPs were separated using a magnetic bed (Ambion). Supernatant was removed, MPs were washed once, and then 20 uL detection antibody (50-500 mg/L diluted in assay buffer) was added and incubated for about 1 hour at 25° C. with shaking The MPs were again magnetically separated and washed 5 times using Tris-buffered saline with 0.5 mL Triton X-100/L. After removal of residual wash buffer, 20 uL elution buffer (Glycine pH 2.5) was added. This reagent disrupted antibody-analyte interactions and resulted in the release of detection antibody from the MPs. The solution in each 96-well plate was then transferred to a 384-well filter plate (0.2 um, AcroPrep cat. no. 5070, Pall) and centrifuged at 1200 g for 3 minutes to separate detection antibody in elution buffer from MPs. The eluted and filtered material in the 384-well plate was then placed into the Erenna Immunoassay System. The concentration of biomarker in each sample was determined via interpolation off a standard curve run with the samples. For samples that used a volume less than 100 ul, the resulting interpolated values were adjusted and standardized to a final sample volume of 100 ul (and 50 ul for cTnI). The value used to convert the standard into pg/mL was provided by the vendor.

All human serum specimens used in this study were obtained from ProMedDx (Norton, Mass.), and obtained under IRB approval and informed consent. All specimens were collected under protocol, which included noting time of blood collection into serum tubes, separation of serum from cells and storing of resulting serum at −70 C. Healthy volunteers (HV) refers to serum collected from otherwise healthy subjects, age range of 42-73 years. Rheumatoid arthritis (RA) refers to serum collected from 17 clinically documented RA patients that had an average rheumatoid factor (RF) value of 75 IU/mL. Approximately 50% of the RA patients were on TNF-a inhibitors. The age range for these subjects was 42-80. 59% were males and 41% were females. Matched controls refers to subjects that were matched in age and sex to the RA subjects, but did not have RA.

Using highly sensitive immunoassays we were able to quantify the concentration of a variety of analytes in serum obtained from HV, RA subjects and matched controls (FIGS. 1, 2). The analytes described in Table 1 and Table 2 were measureable in all study subjects. Importantly, all of the assays had limits of quantification (CV<20%) that were lower than the concentration of the analytes measured in serum. This ensured that the measurement of analyte was accurate. We made the following observations:

Cardiac Troponin-I (cTnI) was elevated in a number of RA patients. Of note the elevations were modest (average approx 11 pg/mL) which was 3-4 fold higher than the average value found in the matched controls (approximately 3 pg/mL). 15/16 of these RA patients had cTnI concentrations<approximately 50 pg/mL, which is the limit of quantification for commercially available cTnI assays. Thus, this small increase (but significant in terms of exceeding the 99% normal range (at CV<10%) of cTnI of 7 pg/ml) in cTnI could not be noted with other assays.

IL-17F was elevated in RA patients compared to matched controls. This is the first time that anyone has found IL-17F to be elevated in RA.

Il-17A was found to be elevated in RA patients. Although the increase in IL-17A was modest (approximately 3-fold) it was highly statistically significant. This is the first time that Il-17A has been shown to be elevated in RA patients compared to controls in plasma and furthermore the magnitude of the elevation was modest and at a low concentration (average approx 1 pg/mL).

Similar to Il-17A, heterodimer Il-17A/F was found elevated in RA patients. This is the first time that the concentrations of this heterodimer have been shown in blood serum from healthy volunteers, or serum from RA patients or matched controls.

IL-6 was found elevated in RA patients versus controls. It has been previously shown that IL-6 is elevated in RA patients; however, it has never been shown that IL-6 elevation correlates with elevations of Il-7A, IL-17F, IL-17A/F, and/or cTnI in some subjects and does not correlate with such elevations in other subjects.

IL-1β was shown to be decreased in RA patients. This is the first time that this serum biomarker has been shown to be down-regulated in RA.

The measurement of differences in the biomarker concentrations, either up- or down-regulated, singly or in combination, in RA patients versus control subjects provides opportunities for better (e.g., simpler, earlier, faster) disease diagnosis, disease staging, risk classification, disease progression, disease severity and/or identification of therapy responders/non-responders.

TABLE 1 Comparison of biomarker concentrations in healthy volunteer (HV) blood donors and subjects with rheumatoid arthritis. Sample Healthy RA Volume Biomarker Unit Mean ± SD Range Mean ± SD Range p-Value (ul) CRP ng/mL 3.5 ± 3.0 0.8-8.8 11.4 ± 16.0  0.4-49.3 0.4188 0.0005 TNF RI ng/mL 2.4 ± 0.6 1.4-3.7 2.5 ± 0.8 1.5-3.9 0.9142 0.1 TNF RII ng/mL 6.2 ± 1.8 3.6-9.8 7.3 ± 2.5  3.7-13.1 0.2811 0.01 totMMP-9 ng/mL 5.1 ± 1.9 2.4-8.6 2.8 ± 1.6 0.9-7.1 0.0043 0.001 proMMP-9 ng/mL 1.0 ± 0.3 0.5-1.5 0.6 ± 0.4 0.2-1.3 0.0461 0.05 IL-1 RA ng/mL 1.2 ± 0.4 0.7-2.0 0.8 ± 0.5 0.2-1.7 0.0753 10 TIMP-2 pg/mL 156 ± 16  140-192 156 ± 30   91-204 0.6273 0.01 MMP-2/TIMP2 pg/mL 76 ± 12 61-95 79 ± 15  43-105 0.4182 0.1 IL-17F pg/mL 41 ± 32  16-116  579 ± 1002  63-3937 0.0002 10 TNFα pg/mL 7.9 ± 1.6  5.9-11.0 16.4 ± 31.5  5.0-129.9 0.905 10 cTnI pg/mL 2.3 ± 1.0 1.3-4.5 11.5 ± 23.1  1.3-95.9 0.1042 20 IL-6 pg/mL 1.7 ± 1.7 0.6-5.9 3.1 ± 2.3 0.7-7.0 0.0423 5 IL-1β pg/mL 2.2 ± 1.0 1.1-3.9 0.44 ± 0.18 0.25-0.90 0.0003 40 IL-17A pg/mL 0.13 ± 0.03 0.07-0.18 0.36 ± 0.28 0.11-1.30 0.0033 100 IL-17A/F pg/mL 0.73 ± 0.35 0.37-1.35 1.81 ± 1.73 0.56-7.14 0.0033 100 Note: one RA pt was excluded from the IL-1β calculations due to the 99.99% probability of the value being an outlier (>4 SD from the mean; 30.11 pg/ml)

TABLE 2 Comparison of biomarker concentrations in healthy volunteer (HV) blood donors and subjects with rheumatoid arthritis (median values). Healthy RA Biomarker Unit Median Median CRP ng/mL 2.62 3.79 TNF RI ng/mL 2.34 2.35 TNF RII ng/mL 6.23 7.05 totMMP-9 ng/mL 5.01 2.65 proMMP-9 ng/mL 0.96 0.68 IL-1 RA ng/mL 1.25 0.55 TIMP-2 pg/mL 148 148 MMP-2/TIMP2 pg/mL 72 78 IL-17F pg/mL 30.4 190 TNFα pg/mL 7.5 7.6 cTnI pg/mL 2.1 4.1 IL-6 pg/mL 1.0 2.0 IL-1β pg/mL 2.26 0.44 IL-17A pg/mL 0.14 0.32 IL-17A/F pg/mL 0.62 1.15

TABLE 3 Percent or fold change in plasma biomarker concentration for RA patients versus HV Mean % or fold Healthy RA change change Biomarker Mean ± SD Range Mean ± SD Range p-Value HV to RA HV to RA totMMP-9 5.1 ± 1.9 2.4-8.6 2.8 ± 1.6 0.9-7.1 0.0043 −2.3 −45% proMMP-9 1.0 ± 0.3 0.5-1.5 0.6 ± 0.4 0.2-1.3 0.0461 −0.4 −40% IL-17F 41 ± 32  16-116  579 ± 1002  63-3937 0.0002 +538 +14-fold cTnI 2.3 ± 1.0 1.3-4.5 11.5 ± 23.1  1.3-95.9 0.1042 +9.2 +4-fold IL-6 1.7 ± 1.7 0.6-5.9 3.1 ± 2.3 0.7-7.0 0.0423 +1.4 +82% IL-1β 2.2 ± 1.0 1.1-3.9 0.44 ± 0.18 0.25-0.90 0.0003 −1.76 −80% IL-17A 0.13 ± 0.03 0.07-0.18 0.36 ± 0.28 0.11-1.30 0.0033 +0.23 +2.8-fold IL-17A/F 0.73 ± 0.35 0.37-1.35 1.81 ± 1.73 0.56-7.14 0.0033 +1.08 +2.5-fold Note: one RA pt was excluded from the IL-1β calculations due to the 99.99% probability of the value being an outlier (>4 SD from the mean; 30.11 pg/ml)

TABLE 4 Raw biomarker concentration data, in pg/ml. IL-1 TNF TNF ID# cTnI IL-1b RA RI RII TNFa IL-6 IL-17F IL-17A HV1 1.26 709 1339 3624 8.1 1 31.2 0.14 HV2 4.5 3.87 1303 2126 4650 6.3 0.6 30.4 0.13 HV3 2.2 2.36 1512 2762 6742 8.5 1.7 26.8 0.14 HV4 2.7 1.34 756 1970 5210 6.8 1.1 71.2 0.15 HV5 1.7 3.67 2016 3727 9784 11 2.4 16 0.18 HV6 2.9 1.84 1253 2336 5445 5.9 0.7 20.1 0.07 HV7 1.6 1.06 758 2192 6443 7.5 0.8 33.3 0.16 HV8 1.3 2.54 1362 2485 6232 7.5 5.9 115.8 0.09 HV9 1.9 2.26 796 2426 7397 9.8 1.1 21.2 0.13 RA1 3 0.54 986 2351 5414 6.7 6.8 616.7 0.11 RA2 3.6 0.9 478 2998 7077 7.2 3.2 62.7 0.55 RA3 14.3 0.44 545 2583 7347 5.6 6.5 1417.3 0.51 RA4 5.9 0.38 748 2603 7638 10.6 2.7 139 0.18 RA5 1.3 0.35 341 1629 5211 7.6 2.2 121.5 0.42 RA6 1.6 0.54 1504 2368 7367 10.8 5.9 191.1 0.11 RA7 0.25 432 2273 6345 9.5 1.7 92.4 0.38 RA8 13.7 0.7 515 1815 5368 6.4 1.1 75.5 0.26 RA9 1.3 0.33 286 1870 5377 6.2 1.3 190.1 0.32 RA10 1.5 0.28 244 3853 10460 15.1 1 85.1 0.37 RA11 95.9 30.11 1717 3689 13119 129.9 7 3936.6 1.3 RA12 18.6 0.33 481 1549 3727 7.6 0.7 329.5 0.2 RA13 3.1 0.45 1533 1832 5464 7.4 2 883.2 0.12 RA14 4.5 0.73 842 1987 5612 5 1.2 143.3 0.51 RA15 1.8 0.33 890 3638 11348 10.4 3.3 395.2 0.37 RA16 4.6 0.38 382 3910 9643 0.26 RA17 8.6 0.62 1410 1984 7047 0.19

TABLE 5 Raw biomarker concentration data, in pg/ml, continued. MMP2/ ID# TIMP2 MMP-2 totMMP9 proMMP9 CRP IL-17AF RF HV1 73 54 5239 955 7038 0.37 0 HV2 91 56 6994 1262 903 0.62 0 HV3 67 54 3200 582 4481 0.55 0 HV4 72 54 4236 776 2624 0.52 0 HV5 61 50 5006 942 8790 1.29 0 HV6 70 49 5517 1240 886 0.69 0 HV7 95 69 2377 508 770 0.67 0 HV8 85 58 8556 1493 1059 0.49 0 HV9 71 53 4843 1169 5291 1.35 0 RA1 67 46 7126 1154 8846 0.56 100 RA2 73 49 4691 995 19660 1.57 100 RA3 43 28 3347 1340 33972 1.55 100 RA4 78 56 2724 458 2483 1.13 100 RA5 75 53 4144 797 6812 0.71 86.2 RA6 66 53 3536 860 49340 0.9 68.9 RA7 71 53 1226 209 383 1.12 42.8 RA8 78 61 2329 663 4136 0.75 71 RA9 103 79 1212 157 1360 1.73 92.4 RA10 77 74 900 151 667 0.69 59 RA11 105 85 2690 656 44292 7.14 100 RA12 79 61 2608 742 1395 1.15 44.7 RA13 78 61 1251 277 3792 5.06 82.1 RA14 87 75 3986 993 1054 1.91 43.2 RA15 70 49 2652 733 14137 1.49 63.9 RA16 102 83 1467 173 944 0.91 28.69 RA17 92 74 1828 681 1014 2.39 100

Table 6 shows AuROC as a measure of predictive power for RA. AuROC does not depend on specifying a cut-point and can be interpreted as the probability that a random RA patient will be classified correctly. AuROC>0.8 suggests very good performance. Odds ratios require specification of a somewhat arbitrary cut-point, wherein the large CIs show the uncertainty in the odds ratios caused by small sample size.

TABLE 6 AuROC analysis of RA biomarkers Odds Ratio Marker AuROC p-Value (95% CI) IL-17F 0.941 0.0001 56 (3.3, 2700) IL-17A 0.863 0.0018 16 (1.7, 208)  IL-17 A/F 0.863 0.0018 56 (3.3, 2700) Total MMP-9 0.85 0.0029    0.088 (0.0072, 0.79)    IL-6 0.735 0.051  5 (0.63, 60)   TNFa 0.569 0.5967   3.1 (0.40, 38)  

Although various specific embodiments of the present invention have been described herein, it is to be understood that the invention is not limited to those precise embodiments and that various changes or modifications can be affected therein by one skilled in the art without departing from the scope and spirit of the invention.

The examples given above are merely illustrative and are not meant to be an exhaustive list of all possible embodiments, applications or modifications of the invention. Thus, various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology, immunology, chemistry, biochemistry or in the relevant fields are intended to be within the scope of the appended claims.

It is understood that the invention is not limited to the particular methodology, protocols, and reagents, etc., described herein, as these may vary as the skilled artisan will recognize. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.

Any numerical values recited herein include all values from the lower value to the upper value in increments of one unit provided that there is a separation of at least two units between any lower value and any higher value. As an example, if it is stated that the concentration of a component or value of a process variable such as, for example, size, angle size, pressure, time and the like, is, for example, from 1 to 90, specifically from 20 to 80, more specifically from 30 to 70, it is intended that values such as 15 to 85, 22 to 68, 43 to 51, 30 to 32, etc. are expressly enumerated in this specification. For values which are less than one, one unit is considered to be 0.0001, 0.001, 0.01 or 0.1 as appropriate. These are only examples of what is specifically intended and all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application in a similar manner.

Particular methods, devices, and materials are described, although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention. The disclosures of all references and publications cited herein are expressly incorporated by reference in their entireties to the same extent as if each were incorporated by reference individually. 

1. A method for predicting the risk for developing an inflammatory disorder in a subject, comprising: (a) obtaining a sample from the subject; (b) determining a concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the sample; wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 2. The method of claim 1, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 3. The method of claim 1, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 4. The method of claim 1, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 5. The method of claim 1, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 6. The method of claim 1, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 7. The method of claim 1, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 8. The method of claim 1, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 9. The method of claim 1, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 10. The method of claim 1, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 11. The method of claim 1, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 12. The method of claim 1, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 13. The method of claim 1, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 14. The method of claim 1, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 15. The method of claim 1, wherein when the subject has a concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 16. The method of claim 1, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 17. The method of claim 1, wherein when the subject has a concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 18. The method of claim 1, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder.
 19. The method of claim 1, wherein when the subject has a concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, and a concentration of totMMP-9 less than about 5.0 ng/ml, the subject is predicted to have a greater than normal risk of developing an inflammatory disorder. 20-38. (canceled)
 39. A method for identifying an inflammatory disorder patient who responds to therapy, comprising: (a) obtaining a first sample from the patient; (b) determining a first concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the first sample; (c) administering a therapy to the patient; (d) obtaining a second sample from the patient; and (e) determining a second concentration of each of IL-17A, IL-17A/F, and IL-17F, and optionally one or more of IL-1β, IL-6, totMMP-9, proMMP-9, cTnI, and combinations thereof in the second sample; wherein when the inflammatory disorder patient has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, the inflammatory disorder patient is identified as a patient who responds to therapy.
 40. The method of claim 39, wherein when the patient has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml and of IL-17F of less than about 116 pg/ml, the inflammatory disorder patient is identified as a patient who responds to therapy.
 41. The method of claim 39, wherein when the patient has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with one or more of a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the inflammatory disorder patient is identified as a patient who responds to therapy.
 42. The method of claim 39, wherein when the patient has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml and of IL-17F of less than about 116 pg/ml, in combination with one or more of a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the inflammatory disorder patient is identified as a patient who responds to therapy.
 43. The method of claim 39, wherein when the patient has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the inflammatory disorder patient is identified as a patient who responds to therapy.
 44. The method of claim 39, wherein when the patient has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml and of IL-17F of greater than about 116 pg/ml, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the inflammatory disorder patient is identified as a patient who responds to therapy.
 45. The method of claim 39, wherein when the patient has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, and a second concentration of one or more of IL-17A, IL-17A/F or IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F or IL-17F, the inflammatory disorder patient is identified as a patient who responds to therapy.
 46. The method of claim 39, wherein when the patient has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, and a second concentration of IL-17A, IL-17A/F and IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F and IL-17F, the inflammatory disorder patient is identified as a patient who responds to therapy.
 47. The method of claim 39, wherein when the patient has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A, IL-17A/F or IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F or IL-17F, in combination with one or more of a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the inflammatory disorder patient is identified as a patient who responds to therapy.
 48. The method of claim 39, wherein when the patient has a first concentration of IL-17A, IL-17A/F or IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A, IL-17A/F or IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F or IL-17F, in combination with a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the inflammatory disorder patient is identified as a patient who responds to therapy.
 49. The method of claim 39, wherein when the patient has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A, IL-17A/F and IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F and IL-17F, in combination with one or more of a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, or a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the inflammatory disorder patient is identified as a patient who responds to therapy.
 50. The method of claim 39, wherein when the patient has a first concentration of IL-17A, IL-17A/F and IL-17F greater than healthy volunteer average concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β less than healthy volunteer average concentrations for IL-1β, a concentration of IL-6 greater than healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 less than healthy volunteer average concentrations for totMMP-9, and a second concentration of IL-17A, IL-17A/F and IL-17F substantially the same as healthy volunteer concentrations for IL-17A, IL-17A/F and IL-17F, in combination with a concentration of IL-1β substantially the same as healthy volunteer average concentrations for IL-1β, a concentration of IL-6 substantially the same as healthy volunteer average concentrations for IL-6, and a concentration of totMMP-9 substantially the same as healthy volunteer average concentrations for totMMP-9, the inflammatory disorder patient is identified as a patient who responds to therapy.
 51. The method of claim 39, wherein when the patient has a first concentration of IL-17A greater than about 0.18 pg/ml, of IL-17A/F greater than about 1.35 pg/ml or of IL-17F of greater than about 116 pg/ml, in combination with one or more of a concentration of IL-1β less than about 1.1 pg/ml, a concentration of IL-6 greater than about 1.0 pg/ml, or a concentration of totMMP-9 less than about 5.0 ng/ml, and a second concentration of IL-17A less than about 0.18 pg/ml, of IL-17A/F less than about 1.35 pg/ml or of IL-17F of less than about 116 pg/ml, in combination with one or more of a concentration of IL-1β greater than about 1.1 pg/ml, a concentration of IL-6 less than about 1.0 pg/ml, or a concentration of totMMP-9 greater than about 5.0 ng/ml, the inflammatory disorder patient is identified as a patient who responds to therapy. 52-59. (canceled)
 60. The method of claim 1, wherein the inflammatory disorder is Rheumatoid Arthritis.
 61. The method of claim 1, wherein the inflammatory disorder is Crohn's Disease.
 62. The method of claim 1, wherein the inflammatory disorder is Inflammatory Bowel Disease.
 63. The method of claim 1, wherein the inflammatory disorder is ulcerative colitis.
 64. The method of claim 1, wherein the inflammatory disorder is psoriasis.
 65. The method of claim 1, wherein the inflammatory disorder is Chronic Obstructive Pulmonary Disease. 66-83. (canceled)
 84. The method of claim 39, wherein the inflammatory disorder is Rheumatoid Arthritis.
 85. The method of claim 39, wherein the inflammatory disorder is Crohn's Disease.
 86. The method of claim 39, wherein the inflammatory disorder is Inflammatory Bowel Disease.
 87. The method of claim 39, wherein the inflammatory disorder is ulcerative colitis.
 88. The method of claim 39, wherein the inflammatory disorder is psoriasis.
 89. The method of claim 39, wherein the inflammatory disorder is Chronic Obstructive Pulmonary Disease. 